Lifecore Biomedical
LFCR
82 hedge funds and large institutions have $117M invested in Lifecore Biomedical in 2024 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 34 increasing their positions, 12 reducing their positions, and 11 closing their positions.
290% more call options, than puts
Call options by funds: $425K | Put options by funds: $109K
183% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 12
64% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 11
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
9% more funds holding
Funds holding: 75 → 82 (+7)
0.4% more ownership
Funds ownership: 66.62% → 67.02% (+0.4%)
2% less capital invested
Capital invested by funds: $119M → $117M (-$2.41M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFM
Boothbay Fund Management
New York
|
+$914K |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$635K |
| 3 |
2C
272 Capital
Dallas,
Texas
|
+$627K |
| 4 |
BlackRock
New York
|
+$315K |
| 5 |
DC
Diametric Capital
Boston,
Massachusetts
|
+$310K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VWA
Visionary Wealth Advisors
O'fallon,
Illinois
|
-$2.52M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$519K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$218K |
| 4 |
LCM
Laurion Capital Management
New York
|
-$199K |
| 5 |
Man Group
London,
United Kingdom
|
-$199K |
LFCR Hedge Fund Activity: Q3 2024 in Review
82 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q3 2024, worth a combined $117M — down 2% from $119M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new LFCR positions and 11 closed out — a net gain of 7 holders — while 34 added to existing stakes and 12 trimmed.
The largest buyer was Boothbay Fund Management, adding an estimated $914K. The largest seller was Visionary Wealth Advisors, exiting entirely with an estimated $2.52M sold.
- 82 institutional investors held Lifecore Biomedical (LFCR) as of Q3 2024, up from 75 in Q2 2024.
- Funds reported $117M of Lifecore Biomedical stock for Q3 2024, down 2% quarter-over-quarter.
- 18 funds opened new Lifecore Biomedical positions in Q3 2024 and 11 closed out, a net change of +7 holders.
- The largest Lifecore Biomedical buyer in Q3 2024 was Boothbay Fund Management, an estimated $914K added.
- The largest Lifecore Biomedical seller in Q3 2024 was Visionary Wealth Advisors, an estimated $2.52M sold.
Based on aggregated 13F filings for Q3 2024.